ProCE Banner Series

Are We Treating HBV Early Enough? Symposium 2 on Key Questions in Timely Management of HBV and HDV

In this live webinar, a panel of expert faculty will consider the pros and cons of expanded HBV treatment candidacy for early treatment engagement including adverse effect considerations, cost-effectiveness, and clinical outcomes such as the potential impact on liver disease progression and HCC rates. Hear patient perspectives on treatment through patient clips.

  AMA
Who Should Attend

This program is intended for physicians, both specialists and primary care providers, and other HCPs who care for patients with HBV and/or HDV infection or patients at risk for infection.

All Events

Are We Treating HBV Early Enough? Symposium 2 on Key Questions in Timely Management of HBV and HDV

Past Events

February

29

2024

12:30 PM - 1:30 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Tatyana Kushner, MD, MSCE

Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

ProCE Banner Faculty
Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

ProCE Banner Faculty
Mark S. Sulkowski, MD, FIDSA, FAASLD

Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Topics

  • Welcome, opening remarks, and baseline assessment
  • Current guideline recommendations and limitations
  • Considerations for more expansive treatment
  • Conclusion and question and answer session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
To enhance learners’ knowledge and competence in providing timely screening and treatment for HBV and HDV with a goal of both individual patient benefit and progress toward HBV elimination goals.

Target Audience
This program is intended for physicians, both specialists and primary care providers, and other HCPs who care for patients with HBV and/or HDV infection or patients at risk for infection. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Summarize the pros and cons of early HBV treatment including drug-related considerations, cost-benefit considerations, and impact on patient outcomes
  • Estimate the effects of universal HBV screening and HDV screening in patients with HBV infection on understanding of disease burden 
  • Formulate strategies to optimize HBV and HDV screening and treatment in varied clinical practice settings to achieve favorable patient outcomes

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC and Hepatitis B Foundation. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC, in partnership with Hepatitis B Foundation.

Supported by an educational grant from Gilead Sciences, Inc.